Noema Pharma

The directors of Asarina Pharma have finally found a buyer for the Tourette’s syndrome treatment sepranolone after securing a bittersweet deal with US firm Relmada Therapeutics which comes four months

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

The news that Asarina Pharma is going into liquidation is a disappointment both to the Swedish biotech's shareholders and to Tourette's syndrome patients hoping for safer and more effective therapie

The recent partial success of Vertex Pharmaceuticals Incorporated ’s non-opioid product VX-548 in a pair of acute pain studies positions the product as potentially the first new non-opioid analgesic